<DOC>
	<DOCNO>NCT02832947</DOCNO>
	<brief_summary>Aim clinical Trial assessment rivaroxaban PK/PD parameter patient 6-8 month bariatric surgery</brief_summary>
	<brief_title>PK Rivaroxaban Bariatric Patients - Extension</brief_title>
	<detailed_description>Weight loss bariatric surgery putatively alter drug disposition rivaroxaban . This may due alter intestinal adaptation several month surgical procedure . The aim clinical trial investigate pharmacokinetic pharmacodynamic parameter single application 10 mg rivaroxaban patient prior bariatric intervention ( Roux-en-y-gastric bypass sleeve gastrectomy 6-8 month ago ) . PK/PD parameter assess 12 hour application rivaroxaban .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Patient past elective bariatric surgery ( RouxenY gastric bypass surgery sleeve gastrectomy 68 month ago ) Patient age 18 year old BMI â‰¥ 35 kg/m2 Women childbearing age : Willingness use double barrier contraception method study Written , inform consent Intake oral anticoagulant ( phenprocoumon , acenocoumarol , dabigatran , etexilate , apixaban etc . ) 4 week prior inclusion study Application parenteral anticoagulant ( unfractionated heparin , low molecular weight heparin , heparin derivates ( fondaparinux etc . ) 4 week prior inclusion study Pharmacologic platelet inhibition 4 week prior inclusion study Known coagulation disorder ( e.g . Willebrand 's disease , haemophilia ) Evidence deep vein thrombosis pulmonary embolism personal history history first degree relative Medical condition associate increase risk VTE , i.e . active cancer disease , lupus erythematodes chronic inflammatory bowel disease Active , clinically significant bleed Congenital acquire bleed disorder Uncontrolled severe hypertension Active gastrointestinal disease potentially lead bleed disorder : oesophagitis , gastritis , gastroesophageal reflux disease , chronic inflammatory bowel disease Vascular retinopathy Bronchiectasis history pulmonary bleeding Prior stroke TIA Hereditary galactose intolerance , Lapp lactase deficiency , glucoselactose malabsorption Severe renal impairment creatinine clearance ( GFR ) &lt; 30ml/min Positive pregnancy test , pregnancy nurse woman High risk bleeding ( e.g . active ulcerative gastrointestinal disease ) Known intolerance study medication rivaroxaban Concomitant treatment strong CYP3A4 inhibitor ( e.g . ketoconazole , itraconazole , lopinavir , ritonavir , indinavir ) Concomitant treatment Pglycoprotein inhibitor weak moderate CYP3A4 inhibitor ( e.g . erythromycin , azithromycin , diltiazem , verapamil , quinidine , ranolazine , dronedarone , amiodarone , felodipine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>